Summary: Johnson & Johnson will acquire Halda Therapeutics for US$3.05 billion in cash to bolster its cancer treatment pipeline. This acquisition is part of J&J’s strategy to address declining sales of its psoriasis drug Stelara due to biosimilar competition.

Link: https://www.businesstimes.com.sg/companies-markets/jj-buy-halda-therapeutics-us3-05-billion-cash-deal